Joseph Manhede - 08 Jul 2026 Form 3 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Reporting relationship: Principal Accounting Officer
Issuer ticker: RCKT
Reported as of: 08 Jul 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 08 Jul 2026, 19:05:04 UTC
Source filing: View source filing
Reporting owner signature: /s/ Martin Wilson, as attorney-in-fact for Joseph Manhede

Key filing fact

Joseph Manhede filed Form 3 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 08 Jul 2026.

Key facts

This page summarizes Joseph Manhede's Form 3 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 08 Jul 2026, 19:05.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002144095 Primary reporting owner

Manhede Joseph

Relationship: Principal Accounting Officer
Address: C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY
Signature: /s/ Martin Wilson, as attorney-in-fact for Joseph Manhede
Signature date: 08 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCKT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 52,576
Date: 08 Jul 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis that were granted to the Reporting Person on May 4, 2026. One-third (1/3) of such RSUs will become fully vested on May 4, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.

SEC remarks

Exhibit 24: Power of Attorney